KidKraft Announces Appointment of Todd Whitbeck as Chief Financial Officer
28.10.2019 12:00:00 EET | Business Wire | Press release
KidKraft, Inc. (“KidKraft”) announced today Todd Whitbeck, a seasoned executive with more than 30 years of experience in finance and corporate development, has been appointed Chief Financial Officer effective immediately.
Whitbeck has a proven track record of financial expertise and operational leadership across a diverse background of public and private companies, with previous success working with MidOcean Partners, the private equity firm that owns KidKraft. He will oversee global financial operations and work closely with KidKraft’s CEO on continued growth and international expansion as the company builds on a 50-year legacy in the toy and juvenile product industry. Whitbeck will report directly to Geoff Walker, Chief Executive Officer.
“Todd is a seasoned finance executive and his leadership will help drive KidKraft’s growth strategies,” said Geoff Walker, CEO, KidKraft. “I’m excited for his partnership and to welcome him as a key member of our executive team.”
“I look forward to working with Geoff and the team at KidKraft and to leveraging my prior experience to fuel the company’s growth,” said Todd Whitbeck. “Having worked across many industries throughout my career, it’s refreshing after all these years to work with a company that inspires the imaginations of children who will lead future generations.”
Whitbeck was most recently CFO and Head of Business Development, Sales, Marketing and Administrative Functions for CANarchy, a fast-growing collective of local, regional and national craft beer breweries. Previously he was Executive Vice President, CFO & Business Development for Water Pik, Inc. where he led and facilitated a very successful sale of the company, and subsequently led integration efforts for the combined companies. He was CFO for JP Energy, Sears Holdings Corporation (SHC) in the hard goods business units and off-mall retail selling formats, and CompUSA, where he elevated his oversight to CFO through various finance roles as the company grew and was acquired. He is a board member for Tufts Health Plan Board of Directors.
An industry leader in design and development of children’s toys and furniture, KidKraft is focused on inspiring imaginative play experiences through high quality products. The company's innovative portfolio includes dollhouses, play kitchens, outdoor playsets, children's furniture, wooden dolls and vehicles and more, offering a variety of different play experiences this holiday season. The company was acquired by MidOcean Partners (“MidOcean”), a premier middle market private equity firm focused on consumer and business services, in July 2015.
About KidKraft, Inc.
KidKraft is a global leader in award-winning products that are MADE FOR MAKE BELIEVE™. The company is committed to inspiring imaginative play creatively for children everywhere through dollhouses, kitchens, outdoor, vehicles, furniture, and toys. KidKraft’s high-quality products, designed for traditional play, are available at more than 2,800 retailers in more than 90 countries worldwide. KidKraft’s global headquarters are located in Dallas, Texas. For more information, visit www.kidkraft.com and follow @kidkrafttoys on Instagram.
About MidOcean Partners
MidOcean Partners is a premier New York-based alternative asset manager that specializes in middle market private equity and alternative credit investments. Since its inception in 2003, MidOcean Private Equity has managed approximately $4.8 billion of committed capital and has targeted investments in high-quality middle market companies in the consumer and business services sectors. MidOcean Credit Partners was launched in 2009 and manages approximately $8 billion across a series of alternative credit strategies, collateralized loan obligations (CLOs), and customized separately managed accounts as of September 30, 2019.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005062/en/
Contact information
Litzky Public Relations on behalf of KidKraft
Kelsey Wheeler
Litzky Public Relations
201/222-9118
kidkraft@litzkypr.com
MidOcean Media Relations
Nathaniel Garnick/Amanda Klein
Gasthalter & Co.
212/257-4170
midocean@gasthalter.com
MidOcean Investor Relations
Allison Donohue
Investorrelations@midoceanpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom